Iron Deficiency Anemia Across Specialties: Optimizing Patient Outcomes through Collaborative Care - Episode 15

Treatment-Emergent Hypophosphatemia Following Administration of Intravenous Iron

Published on: September 6, 2024

Michael Auerbach, MD, Layla Van Doren, MD, Jordan Axelrad, MD, MPH, Steven Fein, MD, MPH, Ashley Benson, MD

The panel discusses the mechanism of treatment-emergent hypophosphatemia that occurs following the administration of certain intravenous iron formulations.

EP. 1: Introduction and Overview of the Physiological Role of Iron Metabolism

EP. 2: Defining Iron Deficiency

EP. 3: Common Causes of Iron Deficiency

EP. 4: Confirming Iron Deficiency Diagnosis

EP. 5: The Clinical Role of Intravenous Iron

EP. 6: Unmet Need for Addressing the Use of IV Iron

EP. 7: Real-World Applications of Intravenous Iron

EP. 8: Overview of Iron Formulations

EP. 9: Generic Formulations of Iron

EP. 10: Dose Timing with Intravenous Iron

EP. 11: Safety of Intravenous Iron

EP. 12: Infusion Reactions to Intravenous Iron

EP. 13: How to Manage Infusion Reactions with Intravenous Iron

EP. 14: Practical Tools for the Administration of Intravenous Iron

Now Viewing

EP. 15: Treatment-Emergent Hypophosphatemia Following Administration of Intravenous Iron

EP. 16: Collaboration and Communication Across the Healthcare Team

Video content above is prompted by the following:

Treatment-emergent hypophosphatemia is now widely recognized as a phenomenon that can occur following administration of certain IV iron formulations and within the first 2 weeks after administration. Can you discuss the mechanism of treatment-emergent hypophosphatemia?